TRIM21 promotes resistance to radiotherapy though degradation of VDAC2 suppressing type I interferon responses.[14] TRIM21 inhibits glioma cell senescence, promotes malignant phenotypes, and enhances temozolomide treatment resistance.[15] In gastrointestinal stromal tumors, TRIM21 ubiquitinates ACSL4 leading to imatinib resistance.[13] Nonetheless, the biological roles and molecular mechanisms of TRIM21 in PC has been limitedly reported. This evidence concerns the gene TRIM21 and pachyonychia congenita.